Opendata, web and dolomites

miPLUNGER SIGNED

Novel premium pre-filled syringe plunger made by micro- /injection moulding for innovative drug delivery systems and auto injectors

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "miPLUNGER" data sheet

The following table provides information about the project.

Coordinator
MDX DEVICES GMBH 

Organization address
address: DAUCHINGER STRASSE 5
city: DEISSLINGEN
postcode: 78652
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2020-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MDX DEVICES GMBH DE (DEISSLINGEN) coordinator 50˙000.00

Map

 Project objective

The global pre-filled syringes (PFS) market has currently a volume of more than 4 billion USD and is growing with a CAGR of 10% due to the increase of chronic diseases, growing demand of biologics and biosimilars and a high penetration rate of autoinjection devices. The segment of autoinjectors grows even faster with a CAGR of 24%. But there are challenges, that cannot be fully solved by the current generation of rubber syringe plungers. Biologics are very sensitive to any leachables, that can be extracted from the syringe components. Self-injection devices need an excellent gliding behaviour of the plunger to minimise patients pain-experience during the injection. The innovative miPLUNGER can solve these challenges by introducing a cost-efficient two component TPE/PFA plunger element, that is manufactured in a reliable two-step micro injection moulding process. The new material is inherently free of any harmful leachables and provides excellent gliding behaviour. The process allows a cost-efficient sterile production under cleanroom conditions in just two process steps and a high flexibility in the plunger design. MDX’ customers are the PFS manufacturers, the primary users of miPLUNGER will be producers of sensitive high-value drugs and those of advanced self-injection devices. MDX will cooperate with them early in their drug and device development to create a growing market for miPLUNGER. By making and selling its new plungers to the PFS producers, MDX anticipates a turnover of 9.6 million €, and an total staff headcount of 28 employees in 2024. In the feasibility study, a detailed analysis of the best-fitting market segments will be conducted, including the cooperation with pilot customers for the validation of the business idea, as well as the elaboration of a thorough business plan for commercialisation. The results of the feasibility study will be integrated into the subsequent SME Phase 2 project to facilitate the commercial launch of miPLUNGER.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MIPLUNGER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MIPLUNGER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More  

Presque (2019)

Smart Nursing Bra

Read More